低收入和中等收入国家流感疾病与疫苗接种的成本及成本效果:2012年至2022年系统综述
该研究系统检索了2012年至2022年发表的低收入和中等收入国家流感经济评估研究,共纳入54项研究,其中26项报告成本效果、24项报告疾病成本、5项报告项目成本。多数成本效果研究(88%)按各自阈值判定至少一个情景具有成本效果或节省成本。作者指出研究间存在显著异质性,仍需在低收入国家和代表性不足人群中继续评估,并建议采用标准化方法。
要点
- 54项研究中26项报告成本效果、24项报告疾病成本、5项报告项目成本,覆盖上中等收入国家12个、下中等收入国家7个、低收入国家3个。
- 成本效果研究中88%按各自设定阈值判定至少一个目标组情景为成本效果或节省成本。
- 作者指出研究间异质性显著,低收入国家及医务人员、孕妇等群体证据仍不足。
核心结论
- 2012年至2022年低收入和中等收入国家关于流感疾病与疫苗接种的经济证据有所增加,但研究间存在显著异质性,仍需在低收入国家及代表性不足人群中继续评估疾病经济负担和疫苗接种成本/成本效果。
研究设计与样本
- 系统综述,2022年1月和2023年10月检索Medline、Embase、Cochrane Library、CINAHL和Scopus,纳入2012年至2022年发表、包含至少1个低收入或中等收入国家数据的原创同行评议研究。
- 共纳入54项研究,其中26项报告成本效果、24项报告疾病成本、5项报告项目成本。
- 纳入国家分类为上中等收入国家12个、下中等收入国家7个、低收入国家3个。
主要发现
- 评估最多的目标人群为儿童(26项研究)、老年人(17项)和慢性病患者(12项),评估孕妇(9项)、医务人员(5项)和集中居住环境人群(1项)的研究较少。
- 疾病成本在上中等收入国家通常高于下中等收入国家/低收入国家,但以占国内生产总值和国民卫生支出的百分比衡量的最高国家经济负担来自一个低收入国家。
- 在评估流感疫苗引入成本效果的研究中,88%按研究设定的阈值将每个目标人群至少一个情景判定为成本效果或节省成本。
局限性
- 纳入研究间存在异质性。
- 所用纳入标准具有限制性。
- 使用哨点监测系统可能遗漏流感负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Historically, lack of data on cost-effectiveness of influenza vaccination has been identified as a barrier to vaccine use in low- and middle-income countries. We conducted a systematic review of economic evaluations describing (1) costs of influenza illness; (2) costs of influenza vaccination programs; and (3) vaccination cost-effectiveness from low- and middle-income countries to assess if gaps persist that could hinder global implementation of influenza vaccination programs. METHODS AND FINDINGS: We performed a systematic search in Medline, Embase, Cochrane Library, CINAHL, and Scopus in January 2022 and October 2023 using a combination of the following key words: "influenza" AND "cost" OR "economic." The search included studies with publication years 2012 through 2022. Studies were eligible if they (1) presented original, peer-reviewed findings on cost of illness, cost of vaccination program, or cost-effectiveness of vaccination for seasonal influenza; and (2) included data for at least 1 low- or middle-income country. We abstracted general study characteristics and data specific to each of the 3 study types. Of 54 included studies, 26 presented data on cost-effectiveness, 24 on cost-of-illness, and 5 on program costs. Represented countries were classified as upper-middle income (UMIC; n = 12), lower-middle income (LMIC; n = 7), and low-income (LIC; n = 3). The most evaluated target groups were children (n = 26 studies), older adults (n = 17), and persons with chronic medical conditions (n = 12); fewer studies evaluated pregnant persons (n = 9), healthcare workers (n = 5), and persons in congregate living settings (n = 1). Costs-of-illness were generally higher in UMICs than in LMICs/LICs; however, the highest national economic burden, as a percent of gross domestic product and national health expenditure, was reported from an LIC. Among studies that evaluated the cost-effectiveness of influenza vaccine introduction, most (88%) interpreted at least 1 scenario per target group as either cost-effective or cost-saving, based on thresholds designated in the study. Key limitations of this work included (1) heterogeneity across included studies; (2) restrictiveness of the inclusion criteria used; and (3) potential for missed influenza burden from use of sentinel surveillance systems. CONCLUSIONS: The 54 studies identified in this review suggest an increased momentum to generate economic evidence about influenza illness and vaccination from low- and middle-income countries during 2012 to 2022. However, given that we observed substantial heterogeneity, continued evaluation of the economic burden of influenza illness and costs/cost-effectiveness of influenza vaccination, particularly in LICs and among underrepresented target groups (e.g., healthcare workers and pregnant persons), is needed. Use of standardized methodology could facilitate pooling across settings and knowledge sharing to strengthen global influenza vaccination programs.
引用
- Gharpure R, Chard AN, Cabrera Escobar M, et al. Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022. PLoS Med. 2024. PMID: 38181066. doi:10.1371/journal.pmed.1004333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。